Today: 1 July 2026
CoreWeave stock price: CRWV faces lawsuit deadline as Feb. 26 earnings loom
16 February 2026
2 mins read

CoreWeave stock price: CRWV faces lawsuit deadline as Feb. 26 earnings loom

New York, Feb 16, 2026, 13:47 ET — Market has closed.

  • U.S. stock trading takes a break for Washington’s Birthday. Markets pick up again on Tuesday.
  • CoreWeave wrapped up Friday at $96.04, a modest gain of roughly 0.3%.
  • New notices from plaintiff firms flagged a March 13 cutoff for investors aiming to become lead plaintiff in the securities class action.

CoreWeave (CRWV) faces a looming lawsuit deadline as U.S. trading resumes Tuesday, right when investors are gearing up for the company’s next earnings release.

Shares of the AI cloud firm have swung sharply in recent sessions. With the holiday break, traders get a pause to sort through the legal chatter versus what might actually threaten the story here.

It’s a tricky moment. CoreWeave has its fourth-quarter and full-year 2025 earnings set for release on Feb. 26, with the conference call lined up for 5 p.m. Eastern.

A Monday notice flagged that the securities lawsuit—Masaitis v. CoreWeave, Inc., et al.—remains before the U.S. District Court for the District of New Jersey. Investors wanting to serve as lead plaintiff have until March 13 to submit, a move that usually puts them at the helm of the case for the group.

According to court filings dated Jan. 12, the case names CoreWeave and a group of its executives as defendants.

The complaint claims CoreWeave exaggerated its capacity to serve customers and minimized the dangers of depending on just one third-party data center provider. It highlights delays at a Denton, Texas cluster and also references how the market responded when those issues eventually came to light.

Reed Kathrein, partner at Hagens Berman, said in a statement that the firm is looking into “the gap between the company’s assurances and the alleged reality of construction delays.” The probe comes as questions swirl around the issue. MarketScreener

Sell-side views remain somewhere between mixed and upbeat, legal risks notwithstanding. DA Davidson stuck to its buy call, holding the price target at $110, per a note flagged by Insider Monkey. Analyst Alex Platt pointed to the Nvidia deal, calling it the support CoreWeave needs to “sustainably build their future infrastructure.” Insider Monkey

CoreWeave’s relationship with Nvidia is key to the bullish thesis. Back in late January, Nvidia put $2 billion into CoreWeave at $87.20 a share, with CoreWeave specifying the funds would support general expansion rather than snapping up more Nvidia chips.

The risk is clear enough—any hitch in execution or funding, and the stock can turn south in a hurry if data center schedules go sideways. Back in November, CoreWeave cut its yearly revenue outlook because of a holdup with an outside data center partner, sending shares tumbling after hours.

The market’s closed Monday. Eyes turn to Tuesday’s open for a fresh gauge on investor sentiment. Then, on Feb. 26, CoreWeave steps up with earnings, expected to address capacity, spending, and whether the case is spilling over — all before that March 13 court deadline hits.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • ASX 200 trails global indexes in 2026 as key healthcare names dive
    July 1, 2026, 3:42 AM EDT. The ASX 200 barely managed a gain of less than 2.8% for the 2026 financial year, outpaced by major overseas markets. The rise was negative after inflation. US stocks soared, with the S&P 500 up 20.8%, NASDAQ up 28.7%, and Europe's STOXX 600 climbing 19%. Losses for CSL-off 52%-and Cochlear, down almost 60%, weighed on the Australian market. Bank results were mixed; ANZ gained 16% but Commonwealth Bank and NAB lagged. 4D Medical stood out with strong returns while the rest of the market barely moved.
Wells Fargo & Company stock drops 2% as CFO talks loan growth — what traders watch next
Previous Story

Wells Fargo & Company stock drops 2% as CFO talks loan growth — what traders watch next

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop